Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue sup1
Submit an article Journal homepage
113
Views
12
CrossRef citations to date
0
Altmetric
Symposium Paper

13 years of trabectedin, 5 years of Yondelis®: what have we learnt?

Axel Le Cesne Medicine Department, Institut de Cancérologie Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France. [email protected]
Pages s11-s19 | Published online: 10 Jan 2014

References

  • Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized Phase II study of two different schedules. J. Clin. Oncol. 27(25), 4188–4196 (2009).
  • Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for Phase II trials in soft tissue sarcomas. Eur. J. Cancer 38(4), 543–549 (2002).
  • Le Cesne A, Domont J, Cioffi A et al. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. Drugs Today (Barc). 45(6), 403–421 (2009).
  • Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23(3), 576–584 (2005).
  • Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. 22(5), 890–899 (2004).
  • Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol. 22(8), 1480–1490 (2004).
  • Jimeno J, Maki RG, Casali P et al. Therapeutic impact of ET-743 (Yondelis; trabectedin), a new marine-derived compound, in sarcoma. Curr. Opin. Orthop. 14(6), 419–428 (2003).
  • Verweij J, van Glabbeke M. Translating targets into treatment: changes in trial methodology and treatment approaches for soft tissue sarcomas. In: Classification and Treatment of Soft Tissue Sarcomas Educational Book. Perry MC (Ed.). American Society of Clinical Oncology, Alexandria, VA, USA, 522–530 (2003).
  • Ruiz-Soto R, Auger N, Tournay E. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas. Eur. J. Cancer 47(9), 1319–1327 (2011).
  • Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8(7), 595–602 (2007).
  • Penel N, Demetri GD, Blay JY et al. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann. Oncol. 24(2), 537–42 (2012).
  • Cousin S, Blay JY, Bertucci F et al. Growth modulation index and RECIST-based STBSG-EORTC criteria for the assessment of drug activity in advanced soft tissue sarcoma (ASTS) patients (pts). J. Clin. Oncol. 30(Suppl.), Abstract 10014 (2012).
  • Le Cesne A, Yovine A, Blay JY et al. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in Phase II clinical trials. Invest. New Drugs 30(3), 1193–1202 (2012).
  • Verweij J, Lee SM, Ruka W et al. Randomized Phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 18(10), 2081–2086 (2000).
  • Nielsen OS, Judson I, van Hoesel Q et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 36(1), 61–67 (2000).
  • Judson I, Radford JA, Harris M et al. Randomised Phase II trial of PEGylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 37(7), 870–877 (2001).
  • Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J. Clin. Oncol. 13(7), 1600–1608 (1995).
  • Sanfilippo R, Grosso F, Jones RL et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol. Oncol. 123(3), 553–556 (2011).
  • Blay JY. Trabectedin: an emerging therapeutic option in soft tissue sarcoma. Eur. J. Clin. Med. Oncol. 1(2) (2009).
  • López-González A, Cantos B, Tejerina E, Provencio M. Activity of trabectedin in desmoplastic small round cell tumor. Med. Oncol. 28(Suppl. 1), S644–S646 (2011).
  • Martinez-Trufero J, Alfaro J, Felipo F, Alvarez M, Madani J, Cebollero A. Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma. Anticancer Drugs 21(8), 795–798 (2010).
  • Chaigneau L, Kalbacher E, Thiery-Vuillemin A et al. Efficacy of trabectedin in metastatic solitary fibrous tumor. Rare Tumors 3(3), e29 (2011).
  • Le Cesne AL, Cresta S, Maki RG et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur. J. Cancer 48(16), 3036–3044 (2012).
  • Gronchi A, Bui BN, Bonvalot S et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann. Oncol. 23(3), 771–776 (2012).
  • Sanfilippo R, Dileo P, Blay JY et al. Trabectedin (T) in advanced, pre-treated synovial sarcoma (SS): a retrospective analysis of 61 patients from four European institutions and from the Italian Rare Cancer Network. Presented at: 17th Annual Meeting of the Connective Tissue Oncology Society. Prague, Czech Republic, 14–17 November 2012.
  • Grosso F, Jones RL, Blay JY et al. Trabectedin in soft tissue sarcomas (STS) carrying a chromosomal translocation: an exploratory analysis. Presented at: 13th Annual Meeting of the Connective Tissue Oncology Society. Seattle, WA, USA, 1–3 November 2007 (Abstract 900).
  • Blay JY, Leahy MG, Bui BN et al. Randomized multicenter Phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS). J. Clin. Oncol. 30(Suppl.), Abstract TPS10101 (2012).
  • Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol. 23(24), 5484–5492 (2005).
  • Blay JY, von Mehren M, Samuels BL et al. Phase I combination study of trabectedin and doxorubicin in patients with soft tissue sarcoma. Clin. Cancer Res. 14(20), 6656–6662 (2008).
  • Blay JY, Italiano A, Ray-Coquard I et al. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer 13, 64 (2013).
  • Saada E, Rahal C, Ray-Coquard I et al. Rechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma following drug holiday: the experience of the French Sarcoma Group (FSG). J. Clin. Oncol. 30(Suppl.), Abstract 10062 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.